FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to oncology, and can be used in the treatment of breast cancer (BC). According to the invention, the method consists in introducing to a subject suffering from BC, which is resistant to medicinal preparations and has a mutant alpha estrogen receptor, a therapeutically effective quantity of a combination of palbociclib and RAD1901.
EFFECT: use of the invention enables inhibiting the growth and regression of a tumor by means of a synergistic combination effect.
15 cl, 14 tbl, 39 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2745678C2 |
| METHODS OF TREATING CANCER | 2016 |
|
RU2737496C2 |
| METHODS FOR TREATMENT OF OVARIAN CANCER | 2017 |
|
RU2772432C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| COMBINATIONS OF TGFβ INHIBITORS AND CDK INHIBITORS FOR TREATMENT OF BREAST CANCER | 2019 |
|
RU2784852C2 |
| COMBINATION THERAPY FOR TREATMENT OF MAMMARY GLAND CANCER | 2018 |
|
RU2764724C2 |
| COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2017 |
|
RU2769251C2 |
| COMPLEX THERAPY FOR CANCER TREATMENT | 2018 |
|
RU2810487C2 |
